{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:44:01Z","timestamp":1784933041639,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10557-025-07806-x","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T08:13:30Z","timestamp":1763021610000},"page":"1177-1186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Individualizing Thromboprophylaxis: From Fixed Doses to Targeted Low-Molecular-Weight Heparin Use"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5219-6971","authenticated-orcid":false,"given":"Ourania S.","family":"Kotsiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimos","family":"Charalampidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos N.","family":"Malizos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"issue":"2","key":"7806_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10557-021-07251-6","volume":"37","author":"A Vitiello","year":"2023","unstructured":"Vitiello A, Ferrara F. Low molecular weight heparin, anti-inflammatory\/immunoregulatory and antiviral effects, a short update. Cardiovasc Drugs Ther. 2023;37(2):277\u201381. https:\/\/doi.org\/10.1007\/s10557-021-07251-6.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7806_CR2","doi-asserted-by":"publisher","unstructured":"Holbrook A, Schulman S, Witt DM et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis. 9th ed. American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e152S\u2013e184S. https:\/\/doi.org\/10.1378\/chest.11-2295","DOI":"10.1378\/chest.11-2295"},{"issue":"4","key":"7806_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/MBC.0000000000001352","volume":"36","author":"MH Waseem","year":"2025","unstructured":"Waseem MH, Abideen ZU, Rehman N, et al. Comparing fondaparinux and low molecular weight heparin for thromboprophylaxis after hip and knee arthroplasty: a systematic review and meta-analysis. Blood Coagul Fibrinolysis. 2025;36(4):119\u201329. https:\/\/doi.org\/10.1097\/MBC.0000000000001352.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"6","key":"7806_CR4","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s10557-023-07479-4","volume":"38","author":"Y Chen","year":"2024","unstructured":"Chen Y, Fan C, Wang J, Jiang M. Rivaroxaban combined with atorvastatin inhibits acute pulmonary embolism by promoting the expression of NRF2\/NQO1. Cardiovasc Drugs Ther. 2024;38(6):1271\u201387. https:\/\/doi.org\/10.1007\/s10557-023-07479-4.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"7806_CR5","doi-asserted-by":"publisher","first-page":"103364","DOI":"10.1016\/j.otsr.2022.103364","volume":"109","author":"M Abatzis-Papadopoulos","year":"2023","unstructured":"Abatzis-Papadopoulos M, Tigkiropoulos K, Nikas S, et al. The effectiveness and safety of direct oral anticoagulants compared to conventional pharmacologic thromboprophylaxis in hip fracture patients: a systematic review and meta-analysis of randomized controlled trials. Orthop Traumatol Surg Res. 2023;109(2):103364. https:\/\/doi.org\/10.1016\/j.otsr.2022.103364.","journal-title":"Orthop Traumatol Surg Res"},{"key":"7806_CR6","unstructured":"Patel P, Varacallo MA. Low-molecular-weight heparin (LMWH). StatPearls [Internet]; 2025."},{"issue":"1","key":"7806_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/TA.0000000000003738","volume":"94","author":"RN Modi","year":"2023","unstructured":"Modi RN, Borst JM, Kirchberg TN, et al. One size does not fit all: sex bias in pharmacologic venous thromboembolism prophylaxis. J Trauma Acute Care Surg. 2023;94(1):78\u201385.","journal-title":"J Trauma Acute Care Surg"},{"issue":"4","key":"7806_CR8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ijoa.2013.05.008","volume":"22","author":"RJ Hiscock","year":"2013","unstructured":"Hiscock RJ, Casey E, Simmons SW, Walker SP, Newell PA. Peak plasma anti-Xa levels after first and third doses of Enoxaparin in women receiving weight-based thromboprophylaxis following caesarean section: a prospective cohort study. Int J Obstet Anesth. 2013;22(4):280\u20138.","journal-title":"Int J Obstet Anesth"},{"issue":"2","key":"7806_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/XCS.0000000000000709","volume":"237","author":"CJ Pokrzywa","year":"2023","unstructured":"Pokrzywa CJ, Biesboer EA, Figueroa J, et al. Anti-Factor Xa monitoring of Enoxaparin thromboembolism prophylaxis in emergency general surgery patients. J Am Coll Surg. 2023;237(2):195\u2013203. https:\/\/doi.org\/10.1097\/XCS.0000000000000709.","journal-title":"J Am Coll Surg"},{"issue":"4","key":"7806_CR10","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s11695-014-1435-3","volume":"25","author":"F Celik","year":"2015","unstructured":"Celik F, Huitema AD, Hooijberg JH, van de Laar AW, Brandjes DP, Gerdes VE. Fixed-dose Enoxaparin after bariatric surgery: the influence of body weight on peak anti-Xa levels. Obes Surg. 2015;25(4):628\u201334.","journal-title":"Obes Surg"},{"key":"7806_CR11","doi-asserted-by":"publisher","first-page":"107602962093119","DOI":"10.1177\/1076029620931194","volume":"26","author":"HA Hakeam","year":"2020","unstructured":"Hakeam HA, Al Duhailib Z, Alsemari M, et al. Anti-factor Xa levels in low-weight surgical patients receiving enoxaparin for venous thromboembolism prophylaxis: a prospective cohort study. Clin Appl Thromb Hemost. 2020;26:1076029620931194. https:\/\/doi.org\/10.1177\/1076029620931194.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"1","key":"7806_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/TA.0b013e3182988c3b","volume":"75","author":"TW Costantini","year":"2013","unstructured":"Costantini TW, Min E, Box K, et al. Dose adjustment of Enoxaparin according to anti-Xa levels increases adequacy of prophylaxis in trauma patients. J Trauma Acute Care Surg. 2013;75(1):33\u20138. https:\/\/doi.org\/10.1097\/TA.0b013e3182988c3b.","journal-title":"J Trauma Acute Care Surg"},{"issue":"1","key":"7806_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00068-019-01215-0","volume":"47","author":"SG Rodier","year":"2021","unstructured":"Rodier SG, Bukur M, Moore S, et al. Weight-based enoxaparin with anti-factor Xa assay-based dose adjustment for venous thromboembolic event prophylaxis in adult trauma patients results in improved prophylactic range targeting. Eur J Trauma Emerg Surg. 2021;47(1):145\u201351. https:\/\/doi.org\/10.1007\/s00068-019-01215-0.","journal-title":"Eur J Trauma Emerg Surg"},{"issue":"8","key":"7806_CR14","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1001\/jamasurg.2019.1165","volume":"154","author":"CJ Pannucci","year":"2019","unstructured":"Pannucci CJ, Fleming KI, Bertolaccini CB, Prazak AM, Huang LC, Pickron TB. Assessment of anti-factor Xa levels of patients undergoing colorectal surgery given once-daily Enoxaparin prophylaxis: a clinical study examining Enoxaparin pharmacokinetics. JAMA Surg. 2019;154(8):697\u2013704. https:\/\/doi.org\/10.1001\/jamasurg.2019.1165.","journal-title":"JAMA Surg"},{"issue":"3","key":"7806_CR15","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.atssr.2023.12.024","volume":"2","author":"H Kim","year":"2024","unstructured":"Kim H, Newman J, Cassiere H, Hartman A, Yu PJ. Inadequate anti-Factor Xa levels with daily 40-mg enoxaparin after cardiac surgery. Annals of Thoracic Surgery Short Reports. 2024;2(3):586\u20139.","journal-title":"Annals of Thoracic Surgery Short Reports"},{"issue":"2","key":"7806_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.surg.2023.04.032","volume":"174","author":"AH Al Tannir","year":"2023","unstructured":"Al Tannir AH, Biesboer EA, Pokrzywa CJ, et al. The efficacy of various enoxaparin dosing regimens in general surgery patients: a systematic review. Surgery. 2023;174(2):315\u201323.","journal-title":"Surgery"},{"issue":"1","key":"7806_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00068-025-02768-z","volume":"51","author":"A Kloub","year":"2025","unstructured":"Kloub A, Alaieb A, Kanbar A. Anti-Xa guided enoxaparin thromboprophylaxis is associated with less thromboembolism than fixed dose dalteparin in trauma patients admitted to intensive care. Eur J Trauma Emerg Surg. 2025;51(1):97. https:\/\/doi.org\/10.1007\/s00068-025-02768-z.","journal-title":"Eur J Trauma Emerg Surg"},{"issue":"4","key":"7806_CR18","first-page":"874","volume":"68","author":"D Malinoski","year":"2010","unstructured":"Malinoski D, Jafari F, Ewing T, et al. Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients. J Trauma. 2010;68(4):874\u201380.","journal-title":"J Trauma"},{"issue":"4","key":"7806_CR19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1177\/1060028016683970","volume":"51","author":"CK Walker","year":"2017","unstructured":"Walker CK, Sandmann EA, Horyna TJ, Gales MA. Increased enoxaparin dosing for venous thromboembolism prophylaxis in general trauma patients. Ann Pharmacother. 2017;51(4):323\u201331. https:\/\/doi.org\/10.1177\/1060028016683970.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"7806_CR20","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1097\/TA.0000000000003707","volume":"93","author":"A Ebeid","year":"2022","unstructured":"Ebeid A, Cole E, Stallwood-Hall C. The efficacy of weight-based Enoxaparin dosing for venous thromboembolism prophylaxis in trauma patients: A systematic review and meta-analysis. J Trauma Acute Care Surg. 2022;93(2):e71\u20139. https:\/\/doi.org\/10.1097\/TA.0000000000003707.","journal-title":"J Trauma Acute Care Surg"},{"issue":"6","key":"7806_CR21","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1177\/00031348241241620","volume":"90","author":"T Thind","year":"2024","unstructured":"Thind T, Heye T, Henson C, et al. Weight-based dosing for low-molecular-weight heparin (Enoxaparin) administration to achieve optimal VTE prophylaxis in trauma patients. Am Surg. 2024;90(6):1406\u201311. https:\/\/doi.org\/10.1177\/00031348241241620.","journal-title":"Am Surg"},{"issue":"6","key":"7806_CR22","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1177\/000313481508100625","volume":"81","author":"JM Nunez","year":"2015","unstructured":"Nunez JM, Becher RD, Rebo GJ, et al. Prospective evaluation of weight-based prophylactic enoxaparin dosing in critically ill trauma patients: adequacy of AntiXa levels is improved. Am Surg. 2015;81(6):605\u20139.","journal-title":"Am Surg"},{"issue":"1","key":"7806_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/0003134820949519","volume":"87","author":"AE Stutsrim","year":"2021","unstructured":"Stutsrim AE, Eady JM, Collum M, et al. Weight-based enoxaparin achieves adequate anti-Xa levels more often in trauma patients: a prospective study. Am Surg. 2021;87(1):77\u201382. https:\/\/doi.org\/10.1177\/0003134820949519.","journal-title":"Am Surg"},{"key":"7806_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.phrs.2018.02.012","volume":"131","author":"B Gaborit","year":"2018","unstructured":"Gaborit B, Moulin PA, Bege T, et al. Lean body weight is the best scale for venous thromboprophylaxis algorithm in severely obese patients undergoing bariatric surgery. Pharmacol Res. 2018;131:211\u20137.","journal-title":"Pharmacol Res"},{"key":"7806_CR25","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jss.2023.01.018","volume":"287","author":"CK Chang","year":"2023","unstructured":"Chang CK, Higgins RM, Rein L, Peppard WJ, Herrmann DJ, Kindel T. Effectiveness of body mass index-based prophylactic enoxaparin dosing in bariatric surgery patients. J Surg Res. 2023;287:168\u201375.","journal-title":"J Surg Res"},{"key":"7806_CR26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jss.2021.02.034","volume":"265","author":"R Bigos","year":"2021","unstructured":"Bigos R, Solomon E, Dorfman JD, Ha M. A weight- and anti-Xa-guided enoxaparin dosing protocol for venous thromboembolism prophylaxis in intensive care unit trauma patients. J Surg Res. 2021;265:122\u201330. https:\/\/doi.org\/10.1016\/j.jss.2021.02.034.","journal-title":"J Surg Res"},{"issue":"5","key":"7806_CR27","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.amjsurg.2011.12.008","volume":"203","author":"GM Riha","year":"2012","unstructured":"Riha GM, Van PY, Differding JA, Schreiber MA, Oregon, Health & Science University Trauma Research Group. Incidence of deep vein thrombosis is increased with 30\u00a0mg twice daily dosing of Enoxaparin compared with 40\u00a0mg daily. Am J Surg. 2012;203(5):598\u2013602.","journal-title":"Am J Surg"},{"issue":"6","key":"7806_CR28","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.soard.2021.02.023","volume":"17","author":"K O\u2019Connor","year":"2021","unstructured":"O\u2019Connor K, Garcia Whitlock AE, Tewksbury C, Williams NN, Dumon KR. Risk factors for postdischarge venous thromboembolism among bariatric surgery patients and the evolving approach to extended thromboprophylaxis with Enoxaparin. Surg Obes Relat Dis. 2021;17(6):1218\u201325.","journal-title":"Surg Obes Relat Dis"},{"issue":"3","key":"7806_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jbcr\/irab039","volume":"42","author":"BP McKinzie","year":"2021","unstructured":"McKinzie BP, Nizamani R, Jones S, King B, Williams FN. Single-center experience with venous thromboembolism prophylaxis for obese burn patients. J Burn Care Res. 2021;42(3):365\u20138. https:\/\/doi.org\/10.1093\/jbcr\/irab039.","journal-title":"J Burn Care Res"},{"issue":"1","key":"7806_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4212\/cjhp.v68i1.1423","volume":"68","author":"G Egan","year":"2015","unstructured":"Egan G, Ensom MH. Measuring anti-factor Xa activity to monitor low-molecular-weight heparin in obesity: a critical review. Can J Hosp Pharm. 2015;68(1):33\u201347. https:\/\/doi.org\/10.4212\/cjhp.v68i1.1423.","journal-title":"Can J Hosp Pharm"},{"issue":"6","key":"7806_CR31","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.amjsurg.2016.08.010","volume":"213","author":"CJ Pannucci","year":"2017","unstructured":"Pannucci CJ, Prazak AM, Scheefer M. Utility of anti-factor Xa monitoring in surgical patients receiving prophylactic doses of Enoxaparin for venous thromboembolism prophylaxis. Am J Surg. 2017;213(6):1143\u201352. https:\/\/doi.org\/10.1016\/j.amjsurg.2016.08.010.","journal-title":"Am J Surg"},{"issue":"2","key":"7806_CR32","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/rapm-2023-104571","volume":"49","author":"DS Henshaw","year":"2024","unstructured":"Henshaw DS, Edwards CJ, Dobson SW, et al. Evaluating residual anti-Xa levels following discontinuation of treatment-dose Enoxaparin in patients presenting for elective surgery: a prospective observational trial. Reg Anesth Pain Med. 2024;49(2):94\u2013101.","journal-title":"Reg Anesth Pain Med"},{"issue":"2","key":"7806_CR33","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1177\/00031348211023438","volume":"89","author":"K Kramme","year":"2023","unstructured":"Kramme K, Sarraf P, Shebrain S, Munene G. Safety and efficacy of prophylactic enoxaparin adjusted by anti-factor Xa peak levels in pancreatic surgery. Am Surg. 2023;89(2):300\u20138.","journal-title":"Am Surg"},{"issue":"6","key":"7806_CR34","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1177\/00031348241239926","volume":"90","author":"S Coster","year":"2024","unstructured":"Coster S, Shammout A, Chaney M, et al. Prophylactic enoxaparin dosing using anti-factor Xa levels in hepatic surgery patients: a pilot study. Am Surg. 2024;90(6):1760\u20132.","journal-title":"Am Surg"},{"issue":"1","key":"7806_CR35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00228-014-1760-4","volume":"71","author":"J Diepstraten","year":"2015","unstructured":"Diepstraten J, Janssen EJ, Hackeng CM, et al. Population pharmacodynamic model for low molecular weight heparin Nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint. Eur J Clin Pharmacol. 2015;71(1):25\u201334. https:\/\/doi.org\/10.1007\/s00228-014-1760-4.","journal-title":"Eur J Clin Pharmacol"},{"key":"7806_CR36","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1016\/j.wneu.2021.10.087","volume":"157","author":"CC May","year":"2022","unstructured":"May CC, Cua S, Smetana KS, Powers CJ. Supraprophylactic Anti-Factor Xa levels are associated with major bleeding in neurosurgery patients receiving prophylactic Enoxaparin. World Neurosurg. 2022;157:e357\u201363. https:\/\/doi.org\/10.1016\/j.wneu.2021.10.087.","journal-title":"World Neurosurg"},{"issue":"5","key":"7806_CR37","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1177\/08971900211004837","volume":"35","author":"R Briggler","year":"2022","unstructured":"Briggler R, Matherne E, Johnson C, Boehmer K. Recurrent thrombi in an obese patient with history of bariatric surgery despite anti-Xa therapy. J Pharm Pract. 2022;35(5):811\u20136. https:\/\/doi.org\/10.1177\/08971900211004837.","journal-title":"J Pharm Pract"},{"issue":"4","key":"7806_CR38","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s12185-011-0933-5","volume":"94","author":"K Yoshida","year":"2011","unstructured":"Yoshida K, Wada H, Hasegawa M, et al. Monitoring for anti-Xa activity for prophylactic administration of Fondaparinux in patients with artificial joint replacement. Int J Hematol. 2011;94(4):355\u201360. https:\/\/doi.org\/10.1007\/s12185-011-0933-5.","journal-title":"Int J Hematol"},{"issue":"5","key":"7806_CR39","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s12185-016-1963-9","volume":"103","author":"M Ikejiri","year":"2016","unstructured":"Ikejiri M, Wada H, Yamaguchi T, et al. Comparison of three different anti-Xa assays in major orthopedic surgery patients treated with Fondaparinux. Int J Hematol. 2016;103(5):554\u20139. https:\/\/doi.org\/10.1007\/s12185-016-1963-9.","journal-title":"Int J Hematol"},{"issue":"3","key":"7806_CR40","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3390\/jcm12031161","volume":"12","author":"H Wang","year":"2023","unstructured":"Wang H, Liu J, Lai X, Li X, Huang W. The role of anti-factor Xa activity in the management of ecchymosis in patients receiving Rivaroxaban after total knee arthroplasty. J Clin Med. 2023;12(3):1161. https:\/\/doi.org\/10.3390\/jcm12031161.","journal-title":"J Clin Med"},{"issue":"3","key":"7806_CR41","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jamcollsurg.2019.11.012","volume":"230","author":"K Kramme","year":"2020","unstructured":"Kramme K, Sarraf P, Munene G. Prophylactic enoxaparin adjusted by anti-factor Xa peak levels compared with recommended thromboprophylaxis and rates of clinically evident venous thromboembolism in surgical oncology patients. J Am Coll Surg. 2020;230(3):314\u201321. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2019.11.012.","journal-title":"J Am Coll Surg"},{"issue":"3","key":"7806_CR42","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.atssr.2024.04.014","volume":"2","author":"RS Martins","year":"2024","unstructured":"Martins RS, Christophel E, Poulikidis K, et al. Variations in perioperative thromboprophylaxis practices: do the guidelines need a closer look? Annals of Thoracic Surgery Short Reports. 2024;2(3):422\u20136. https:\/\/doi.org\/10.1016\/j.atssr.2024.04.014.","journal-title":"Annals of Thoracic Surgery Short Reports"},{"key":"7806_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2025.04.066","author":"RC Palmer","year":"2025","unstructured":"Palmer RC, Telang SS, Dobitsch A, et al. Rivaroxaban utilization without perioperative tranexamic acid is associated with an increased risk of bleeding complications following total joint arthroplasty. J Arthroplasty. 2025. https:\/\/doi.org\/10.1016\/j.arth.2025.04.066.","journal-title":"J Arthroplasty"},{"issue":"1","key":"7806_CR44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00345-024-05372-9","volume":"43","author":"J Najdi","year":"2024","unstructured":"Najdi J, Ayoub CH, Chawareb EA, et al. Preoperative risk factors for venous thromboembolism in major urologic cancer surgeries. World J Urol. 2024;43(1):10. https:\/\/doi.org\/10.1007\/s00345-024-05372-9.","journal-title":"World J Urol"},{"issue":"6","key":"7806_CR45","doi-asserted-by":"publisher","first-page":"731","DOI":"10.14444\/8656","volume":"18","author":"FA AlGhamdi","year":"2024","unstructured":"AlGhamdi FA, Alzayer MO, AlKabbani MM, et al. Meta-analysis investigating optimal timing of chemoprophylaxis for venous thromboembolism in operatively managed blunt spinal injuries. Int J Spine Surg. 2024;18(6):731\u20137. https:\/\/doi.org\/10.14444\/8656.","journal-title":"Int J Spine Surg"},{"issue":"6","key":"7806_CR46","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1097\/TA.0000000000001663","volume":"83","author":"CA Karcutskie","year":"2017","unstructured":"Karcutskie CA, Dharmaraja A, Patel J, et al. Relation of antifactor-Xa peak levels and venous thromboembolism after trauma. J Trauma Acute Care Surg. 2017;83(6):1102\u20137.","journal-title":"J Trauma Acute Care Surg"},{"issue":"8","key":"7806_CR47","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1053\/j.jvca.2024.03.042","volume":"38","author":"S Rajsic","year":"2024","unstructured":"Rajsic S, Breitkopf R, Treml B, et al. Anti-Xa-guided anticoagulation with unfractionated heparin and thrombosis during extracorporeal membrane oxygenation support: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2024;38(8):1662\u201372.","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"11","key":"7806_CR48","doi-asserted-by":"publisher","first-page":"932","DOI":"10.5152\/akd.2014.5723","volume":"15","author":"N Tekkesin","year":"2015","unstructured":"Tekkesin N, Tekkesin M, Kaso G. Thromboelastography for the monitoring of the antithrombotic effect of low-molecular-weight heparin after major orthopedic surgery. Anatol J Cardiol. 2015;15(11):932\u20137. https:\/\/doi.org\/10.5152\/akd.2014.5723.","journal-title":"Anatol J Cardiol"},{"issue":"12","key":"7806_CR49","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1111\/anae.14425","volume":"73","author":"G Erdoes","year":"2018","unstructured":"Erdoes G, Martinez Lopez De Arroyabe B, Bolliger D, et al. International consensus statement on the peri-operative management of direct oral anticoagulants in cardiac surgery. Anaesthesia. 2018;73(12):1535\u201345. https:\/\/doi.org\/10.1111\/anae.14425.","journal-title":"Anaesthesia"},{"issue":"1","key":"7806_CR50","doi-asserted-by":"publisher","first-page":"2503697","DOI":"10.1080\/21548331.2025.2503697","volume":"53","author":"B Teferi Mekonen","year":"2025","unstructured":"Teferi Mekonen B, Shibabaw Molla T, Fentahun Bekalu A, et al. Venous thromboembolism prevention practice and associated factors among orthopedic surgical patients in Ethiopia: a cross-sectional study. Hosp Pract. 2025;53(1):2503697. https:\/\/doi.org\/10.1080\/21548331.2025.2503697.","journal-title":"Hosp Pract"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07806-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-025-07806-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07806-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:21:46Z","timestamp":1778649706000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-025-07806-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7806"],"URL":"https:\/\/doi.org\/10.1007\/s10557-025-07806-x","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"22 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no conflicts of interest relevant to the content of this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}